Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cistron Biotechnology(CIST)$.30 -- Ignore unavailable to you. Want to Upgrade?

To: Rudy Saucillo who wrote (1198)	6/23/1998 1:42:00 PM
From: Rudy Saucillo	Read Replies (2) \| Respond to of 2742

As a benchmark, after a new business plan was developed, it took ONC/Lehman less than 3 months to identify a buyer and finish negotiations for their research products division. When are we going to see tangible results from CIST/BlueStone??? Gaithersburg, Maryland, March 26, 1998 ..... Oncor, Inc. (AMEX: ONC) announced today that as part of the strategic process for which Lehman Bros. was retained, it will concentrate its corporate resources to grow its INFORM™ HER-2/neu breast cancer test business, to expand the use of the test for a broad range of major cancers and to complete the development of its pipeline of predictive oncology tests. To support the growth of its oncology franchise, Oncor is proceeding aggressively to divest its non-core Research Products and non-oncology Genetics business units and secure separate financing for its gene repair therapeutic program, Codon Pharmaceuticals, Inc. <clip> Rudy